Pleiotropic Effects of Simvastatin on the Regulation of Potassium Channels in Monocytes

ConclusionOur data suggested Kv1.3 in monocytes was a potential molecular target of the pleiotropic effects of statins. KCa3.1 might be another marker of CAD, but not associated with statins treatment.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

As yet there's no magic bullet that offers protection against coronavirus. And even though vitamin C supplements are selling in huge quantities, hard evidence on its effectiveness is lacking.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ABSTRACTSeveral epidemiological studies have reported a relationship between statin treatment and increased bone mineral density (BMD) and reduced fracture risk, but the mechanism underlying the purported relationship is unclear. We used Mendelian randomization (MR) to assess whether this relationship is explained by a specific effect in response to statin use or by a general effect of lipid lowering. We utilized 400 single ‐nucleotide polymorphisms (SNPs) robustly associated with plasma lipid levels as exposure. The outcome results were obtained from a heel estimated BMD (eBMD) genomewide association study (GWAS) from t...
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research
To explore the effects of statin therapy with the abdominal aortic aneurysm (AAA) growth rate and mortality.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Tags: General Review Source Type: research
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) particle containing apolipoprotein(a) (apo(a)) covalently linked to apolipoprotein B-100 (apoB). Statin-treated patients with elevated Lp(a) have an increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent trials show that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition decreases Lp(a) and cardiovascular events, particularly in high risk patients with elevated Lp(a). We investigated the kinetic mechanism whereby alirocumab, a PCSK9 inhibitor, lowers Lp(a) in statin-treated patients with high Lp(a) and ASCVD.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
This study aimed to examine whether sappanwood ethyl acetate extract (SEAE) alleviates experimental atherosclerosis in rats through FGF21/SREBP-2 signaling. Rats were randomized to six groups (n=10/group): blank control, model, simvastatin (positive control, 4.2 mg/kg/d), and SEAE high-, medium-, and low-dose (2.30, 1.15, and 0.575 g/kg/d, respectively). The high-fat- and vitamin D3-induced rodent model of atherosclerosis was created (except in the blank control group). Aorta and liver underwent histopathologic examination. SREPB-2 and FGF21 expression levels were examined by real-time RT-PCR and western blot. Compared wit...
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research
Clinical Liver Disease, Volume 15, Issue 2, Page 69-70, February 2020.
Source: Clinical Liver Disease - Category: Gastroenterology Authors: Tags: Review Source Type: research
Hwang Statins such as simvastatin have many side effects, including muscle damage, which is known to be the most frequent undesirable side effect. Lysophosphatidic acid (LPA), a kind of biolipid, has diverse cellular activities, including cell proliferation, survival, and migration. However, whether LPA affects statin-linked muscle damage has not been reported yet. In the present study, to determine whether LPA might exert potential protective effect on statin-induced myocyotoxicity, the effect of LPA on cytotoxicity in rat L6 myoblasts exposed to simvastatin was explored. Viability and apoptosis of rat L6 myoblasts we...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
In conclusion, berberine-induced nuclear translocation of FXR and LXRα could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Risk for heart failure hospital visit declined with statins for women receiving anthracyclines, trastuzumab
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
Condition:   Diabetes Intervention:   Sponsor:   University Hospital, Montpellier Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cholesterol | Drugs & Pharmacology | Potassium | Simvastatin | Statin Therapy | Study | Zocor